1887

Journal of Medical Microbiology logo

Volume 67, Issue 5

evaluation of double-carbapenem combinations against OXA-48-producing isolates using time–kill studies Free

Abstract

The aim of this study was to evaluate the activity of double-carbapenem combinations against OXA-48-producing clinical isolates.

Double combinations of ertapenem, meropenem and imipenem were evaluated for synergy and bactericidal activity using the time–kill methodology. All antibiotics were tested at 10 mg l and at a sub-inhibitory concentration of 0.5× minimum inhibitory concentration (MIC) for isolates with a carbapenem MIC≤8 mg l. Synergy was defined as a ≥2log colony-forming units (c.f.u.) ml decrease of viable colonies at 24 h compared to the most active carbapenem alone.

Ten distinct clinical isolates were tested. All carried and , and exhibited an MIC range of 64–128, 4–32 and 1–32 mg l for ertapenem, meropenem and imipenem, respectively. Out of 48 isolate-combinations, synergy was observed in 9 (18.8 %) and cidal activity was observed in 13 (27.1 %). synergistic activity was noted for 5 out of 29 (17.2 %) ertapenem-, 6 out of 29 (20.7 %) meropenem- and 7 out of 38 (18.4 %) imipenem-containing combinations. No combination exhibited antagonism. Bactericidal activity was observed in 7 (24.1 %) ertapenem-, 8 (27.6 %) meropenem- and 11 (28.9 %) imipenem-containing combinations. Among the sub-inhibitory concentration combinations, three (15 %) ertapenem-, four (20 %) meropenem- and three (15 %) imipenem-containing ones showed synergistic interaction.

Dual combinations of carbapenems, including those containing sub-inhibitory concentrations of antibiotics, were synergistic against multidrug-resistant (MDR) and extensively drug-resistant (XDR) isolates harbouring .

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): carbapenemase , ertapenem , imipenem , meropenem and synergy
© 2018 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000725
2018-05-01
2024-04-20
Loading full text...

Full text loading...

/deliver/fulltext/jmm/67/5/662.html?itemId=/content/journal/jmm/10.1099/jmm.0.000725&mimeType=html&fmt=ahah

References

  1. Poirel L, Héritier C, Tolün V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48:15–22 [View Article][PubMed]
     [Google Scholar]
  2. Dortet L, Oueslati S, Jeannot K, Tandé D, Naas T et al. Genetic and biochemical characterization of OXA-405, an OXA-48-type extended-spectrum β-lactamase without significant carbapenemase activity. Antimicrob Agents Chemother 2015; 59:3823–3828 [View Article][PubMed]
     [Google Scholar]
  3. Samuelsen Ø, Hansen F, Aasnæs B, Hasman H, Lund BA et al. Dissemination and characteristics of a novel plasmid-encoded carbapenem-hydrolyzing class D β-lactamase, OXA-436, found in isolates from four patients at six different hospitals in Denmark. Antimicrob Agents Chemother 2017; 62:e01260-17 [View Article]
     [Google Scholar]
  4. Lee CR, Lee JH, Park KS, Kim YB, Jeong BC et al. Global dissemination of carbapenemase-producing Klebsiella pneumoniae: epidemiology, genetic context, treatment options, and detection methods. Front Microbiol 2016; 7:895 [View Article][PubMed]
     [Google Scholar]
  5. Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 2012; 67:1597–1606 [View Article][PubMed]
     [Google Scholar]
  6. Docquier JD, Calderone V, de Luca F, Benvenuti M, Giuliani F et al. Crystal structure of the OXA-48 beta-lactamase reveals mechanistic diversity among class D carbapenemases. Chem Biol 2009; 16:540–547 [View Article][PubMed]
     [Google Scholar]
  7. Navarro-San Francisco C, Mora-Rillo M, Romero-Gómez MP, Moreno-Ramos F, Rico-Nieto A et al. Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge. Clin Microbiol Infect 2013; 19:E72E79 [View Article][PubMed]
     [Google Scholar]
  8. Paño-Pardo JR, Ruiz-Carrascoso G, Navarro-San Francisco C, Gómez-Gil R, Mora-Rillo M et al. Infections caused by OXA-48-producing Klebsiella pneumoniae in a tertiary hospital in Spain in the setting of a prolonged, hospital-wide outbreak. J Antimicrob Chemother 2013; 68:89–96 [View Article][PubMed]
     [Google Scholar]
  9. Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 2014; 20:862–872 [View Article][PubMed]
     [Google Scholar]
  10. Galani I, Anagnostoulis G, Chatzikonstantinou M, Petrikkos G, Souli M. Emergence of Klebsiella pneumoniae co-producing OXA-48, CTX-M-15, and ArmA in Greece. Clin Microbiol Infect 2016; 22:898–899 [View Article][PubMed]
     [Google Scholar]
  11. The European Committee on Antimicrobial Susceptibility Testing 2018; Breakpoint tables for interpretation of MICs and zone diameters. Version 8.0. www.eucast.org
  12. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268–281 [View Article][PubMed]
     [Google Scholar]
  13. Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis 2008; 47:S32–S40 [View Article][PubMed]
     [Google Scholar]
  14. Rodloff AC, Goldstein EJ, Torres A. Two decades of imipenem therapy. J Antimicrob Chemother 2006; 58:916–929 [View Article][PubMed]
     [Google Scholar]
  15. Nix DE, Majumdar AK, Dinubile MJ. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J Antimicrob Chemother 2004; 53:ii23–ii28 [View Article][PubMed]
     [Google Scholar]
  16. Amsterdam D. Susceptibility testing of antimicrobials in liquid media. In Lorian V. (editor) Antibiotics in Laboratory Medicine, 3rd ed. Baltimore: The Williams and Wilkins Co; 1991 pp. 53–105
     [Google Scholar]
  17. Eliopoulos G, Moellering RC. Antimicrobial combinations. In Lorian V. (editor) Antibiotics in Laboratory Medicine, 3rd ed. Baltimore: The Williams and Wilkins Co; 1991 pp. 432–492
     [Google Scholar]
  18. Poirel L, Kieffer N, Nordmann P. In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother 2016; 71:156–161 [View Article][PubMed]
     [Google Scholar]
  19. Mimoz O, Grégoire N, Poirel L, Marliat M, Couet W et al. Broad-spectrum β-lactam antibiotics for treating experimental peritonitis in mice due to Klebsiella pneumoniae producing the carbapenemase OXA-48. Antimicrob Agents Chemother 2012; 56:2759–2760 [View Article][PubMed]
     [Google Scholar]
  20. Wiskirchen DE, Nordmann P, Crandon JL, Nicolau DP. Efficacy of humanized carbapenem and ceftazidime regimens against Enterobacteriaceae producing OXA-48 carbapenemase in a murine infection model. Antimicrob Agents Chemother 2014; 58:1678–1683 [View Article][PubMed]
     [Google Scholar]
  21. Mathers AJ, Hazen KC, Carroll J, Yeh AJ, Cox HL et al. First clinical cases of OXA-48-producing carbapenem-resistant Klebsiella pneumoniae in the United States: the "menace" arrives in the new world. J Clin Microbiol 2013; 51:680–683 [View Article][PubMed]
     [Google Scholar]
  22. de Jonge BL, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF et al. In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM Global Surveillance Study (2012 to 2014). Antimicrob Agents Chemother 2016; 60:3163–3169 [View Article][PubMed]
     [Google Scholar]
  23. Humphries RM, Hemarajata P. Resistance to ceftazidime-avibactam in Klebsiella pneumoniae due to porin mutations and the increased expression of KPC-3. Antimicrob Agents Chemother 2017; 61:e00537-17 [View Article][PubMed]
     [Google Scholar]
  24. Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2011; 55:3002–3004 [View Article][PubMed]
     [Google Scholar]
  25. Oliva A, D'Abramo A, D'Agostino C, Iannetta M, Mascellino MT et al. Synergistic activity and effectiveness of a double-carbapenem regimen in pandrug-resistant Klebsiella pneumoniae bloodstream infections. J Antimicrob Chemother 2014; 69:1718–1720 [View Article][PubMed]
     [Google Scholar]
  26. Souli M, Karaiskos I, Masgala A, Galani L, Barmpouti E et al. Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis 2017; 36:1305–1315 [View Article][PubMed]
     [Google Scholar]
  27. de Pascale G, Martucci G, Montini L, Panarello G, Cutuli SL et al. Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case-control study. Crit Care 2017; 21:173 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000725
Loading
In vitro evaluation of double-carbapenem combinations against OXA-48-producing Klebsiella pneumoniae isolates using time–kill studies
J. Med. Microbiol. 67, 662 (2018); https://doi.org/10.1099/jmm.0.000725
/content/journal/jmm/10.1099/jmm.0.000725
/content/journal/jmm/10.1099/jmm.0.000725
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error